The purpose of this study is to identify the neurophysiologic indicators of cocaine or methamphetamine use and withdrawal, to examine the relationship between subjects' reports of depression, craving, and stimulant use, and neurophysiologic measures, and to identify neurophysiologic measures which can be used to identify new treatments for stimulant dependence.

Condition	Treatment or Intervention	Phase
Substance-Related Disorders	Behavior: NA	Phase IV

Further Study Details: 

Expected Total Enrollment:  90

By Incorporating QEEG into clinical trails, the plan is to develop physiologic markers of treatment efficacy, and to aid in the identification of effective treatments.

Ages Eligible for Study:  21 Years   -   50 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

California
      Friends Research Institute, Los Angeles,  California,  90025,  United States

Study chairs or principal investigators

Walter Ling, M.D.,  Principal Investigator,  Friends Research Institute   

Study ID Numbers:  NIDA-3-0010-8; Y01-3-0010-8
Record last reviewed:  April 1996
Last Updated:  December 3, 2004
Record first received:  September 20, 1999
ClinicalTrials.gov Identifier:  NCT00000343
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08